Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.54 |
| ▸ | ITGAV | P06756 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091870 | 1.00 | ITGB3 (0.54) | ITGB3ITGAVGAAMAPTCTSS | |
| SCHEMBL7414295 | 0.89 | CAPN1 (0.60) | CTSSCTSKCTSLCTSBCASP1 | |
| SCHEMBL7420942 | 0.85 | CAPN1 (0.59) | CTSSCTSKCTSLCTSBCASP1 | |
| SCHEMBL23574534 | 0.85 | CTSK (0.54) | CTSSCTSKCTSLCTSBCASP1 | |
| SCHEMBL11167471 | 0.85 | CTSK (0.54) | CTSSCTSKCTSLCTSBCASP1 | |
| SCHEMBL613386 | 0.84 | CASP1 (0.67) | CASP1PPARGPPARA | |
| SCHEMBL554032 | 0.84 | CASP1 (0.67) | CASP1PPARGPPARA | |
| SCHEMBL376886 | 0.84 | CASP1 (0.67) | CASP1PPARGPPARA | |
| SCHEMBL8085158 | 0.84 | ITGB3 (0.60) | ITGB3CTSSCTSKCTSLCTSB | |
| SCHEMBL7583002 | 0.83 | CASP1 (0.60) | CTSSCTSKCTSLCTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470782-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-06-25 | — | — | US | disclosed |
| US-8153593-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-11-24 | — | — | US | disclosed |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; AND THE WASHINGTON UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| US-7579313-B2 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-02-12 | — | — | US | disclosed |
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-02-21 | — | — | US | disclosed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-03-09 | — | — | US | disclosed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | ITGB3 3613/4885ITGAV 3154/4885GAA 60/4885 |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | TGM2, TGM3, TGM1 | ITGB3 1426/4885ITGAV 2287/4885GAA 11/4885 |
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | SI, DNPEP, SPINT2 | ITGB3 3613/4885ITGAV 3154/4885GAA 60/4885 |
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | SI, DNPEP, SPINT2 | ITGB3 3613/4885ITGAV 3154/4885GAA 60/4885 |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | MGMT, GMFG, HNMT | ITGB3 3863/4885ITGAV 4169/4885GAA 130/4885 |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | SI, DNPEP, SPINT2 | ITGB3 3613/4885ITGAV 3154/4885GAA 60/4885 |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | TGM2, TGM3, TGM1 | ITGB3 1426/4885ITGAV 2287/4885GAA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.